Undisclosed PARP7 inhibitor / Dong-A - LARVOL DELTA

A novel PARP7 inhibitor exhibits dual antitumor activity through immune activation and tumor-intrinsic growth inhibition (AACR 2026) - "Notably, across both mechanisms, compound 1 demonstrated comparable or superior activity to RBN2397, a PARP7 inhibitor under clinical evaluation. In summary, our findings highlight PARP7 inhibition as a promising therapeutic strategy that integrates immune activation with tumor-intrinsic growth inhibition. The novel PARP7 inhibitor, compound 1, consistently demonstrated this dual mechanism across diverse preclinical models, supporting its potential as a next-generation therapeutic candidate with both immune-mediated and tumor-intrinsic antitumor activity."

IO biomarker • Oncology • TIPARP

Dual mechanisms of PARP7 inhibition driving potent antitumor activity (AACR 2026) - "We have developed a couple of series of novel PARP7 inhibitors, and in this study, we focused on characterizing the molecular features associated with responsiveness to PARP7 inhibitors in parallel with mechanistic studies using the clinical-stage benchmark, RBN-2397. Collectively, our findings demonstrate that PARP7 inhibition elicits a dual mechanism involving ISG induction and intrinsic cytotoxicity, resulting in robust antitumor activity. The key regulatory factors underlying this dual mechanism may serve as potential biomarkers for patient selection in future clinical trials and help identify individuals most likely to benefit from PARP7-targeted therapy."

IO biomarker • Oncology • TIPARP